Clinical trial / 2007
Oral beta glucan increased peripheral blood monocyte count and activation in advanced breast cancer.
Researchers evaluated the in vivo effects of daily oral 1-3, 1-6, D-beta glucan given for 15 days to 23 women with advanced breast cancer. Mean monocyte counts increased significantly from 326/mm3 to 496/mm3 (p=0.015). CD14-positive monocyte expression of CD95 rose from 48.17% to 69.23% (p=0.002) and CD45RA expression rose from 49.9% to 61.52% (p=0.001).
- Study type
- Prospective clinical trial
- Who was studied
- 23 women with advanced breast cancer and 16 healthy controls
- What was measured
- Monocyte count and expression of activation markers
THE PAPER
Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer.
Demir G, Klein HO, Mandel-Molinas N, Tuzuner N. Int Immunopharmacol, 2007.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.